Blog

PharmaTher Announces Positive Research Results for LSD Microneedle Patch

Dec 14 • 3 min read

PharmaTher Holdings Ltd. (CSE: PHRM), a clinical-stage psychedelics biotech company, is pleased to announce that it has successfully completed its first research study evaluating MicroDose-MN™, a proprietary microneedle patch for the intradermal delivery of psychedelics, in delivering lysergic acid diethylamide. These results provide support to file for an IND application with the FDA to conduct…

Numinus Wellness Inc. Reports Q4 and Year End 2021 Results

Dec 13 • 6 min read

Numinus Wellness Inc. (TSXV: NUMI), a mental health care company advancing innovative treatments and safe, evidence-based psychedelic-assisted therapies, today announced its fiscal fourth quarter and full year results for the periods ended August 31, 2021. “During the fourth quarter we were focused on building the team, infrastructure, technologies and protocols that will allow us to scale…

A New Cross-Sector Partnership Means a Huge Step Forward for MDMA Therapy

Dec 10 • 2 min read

A for-profit corporation and a non-profit organization are teaming up to help bring MDMA-assisted therapy to PTSD patients… Health and wellness fund Vine Ventures and the Multidisciplinary Association for Psychedelic Studies (MAPS) announced that they’re co-creating a special purpose vehicle (SPV). The SPV, which will be called the Regenerative Financing Vine (RFV), will have the…

How to Effectively Market Your Psychedelic Brand

Dec 10 • 6 min read

As you likely know, we are in the midst of a “shroom boom” and a “green wave”, with psilocybin mushrooms, marijuana, CBD, and psychedelic substances receiving a lot of media attention. In many states, these substances are either being pushed towards decriminalization or being heavily researched in their use for therapeutic purposes. The Growing Psychedelic…

Cybin Confirms Scientific Advice Meeting with UK Medical and Healthcare Products Regulatory Agency for Lead Candidate CYB003

Dec 10 • 3 min read

Cybin Inc. (NYSE: CYBN), a biopharmaceutical company focused on progressing “Psychedelics to Therapeutics™” is pleased to announce that it has confirmed a scientific advice meeting with the UK Medical and Healthcare Products Regulatory Agency for the first quarter of calendar year 2022. This program milestone brings the Company closer toward advancing its lead investigational candidate CYB003…

Pages: 123456789101112131415161718192021222324252627282930313233343536373839404142434445464748495051525354555657585960616263646566676869707172737475767778798081828384858687888990919293949596979899100101102103104105106107108109110111112113114115116117118119120121122123124125126127128129130131132133134135136137138139140141142143144145146147148149150151152153154155156157158159160161162163164165166167168169170171172173174175176177178179180181182183184185186187188189190191192193194195196197198199200201202203204205206207208209210211212213214215216217218219220221222223224225226227228229230231232233234235236237238239240241242243244245246247248249250251252253254255256257258259260261262263264265266267268269270271272273274275276277278279280281282283284285286287288289290291292293294295296297298299300301302303304305306307308309310311312313314315316317318319320321322323324325326327328329330331332333334335336337338339340341342343344345346347348349350351352353354355356357358359360361362363364365366367368369370371372373374375376377378379380381382383384385386387388389390391392393394395396397398399400401402403404405406407408409410411412413414415416417418419420421422423424425426427428429430431432433434435436437438439440441442443444445446447448449450451452453454455456457458459460461462463464465466467468469470471472473474475476477478479480481482483484485486487488489490491492493494495496497498499500501502503504505506507508509510511512513514515516517518519520521522523524525526527528529530531532533534535536537538